For many years, it seemed difficult to develop non-opioid drugs for chronic neuropathic pain.

Algiax proves the opposite with promising data from its Phase II study showing “clinically meaningful” pain reduction in patients with peripheral post-surgical neuropathic pain.
More than a quarter of patients treated with the GABAA-receptor modulator experienced at least a 50% reduction in pain, compared to 11% of placebo patients. The Phase 2a study enrolled almost 100 patients at various sites in Germany, France, Spain, the Czech Republic and Belgium.
The lead compound AP-325 was well-tolerated, with no serious adverse events or side effects on the central nervous system. In contrast to conventional treatments that affect the central nervous system, AP-325 avoids common side effects such as addiction and dizziness.
The drug’s safety and efficacy are attributed to its peripheral mechanism of action, which restores inhibitory control in the nervous system and reduces pain.
Big congratulations to the entire Algiax team on this great achievement! We are proud to support your mission to revolutionize chronic neuropathic pain treatment.
More information in the press release under the following link